Watch ADVB. Know when insiders buy.
One email the day a filing lands. Free.
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Mar 31 | — | — | — | — | −$489K | — | -0.38 | −$240K | $1K | −$241K | May 15 |
| Q2 2026 · Dec 31 | — | — | — | — | $6.9M | — | 0.31 | −$514K | $13K | −$526K | Feb 13 |
| Q1 2026 · Sep 30 | — | — | — | — | −$387K | — | -0.02 | −$610K | $2K | −$612K | Nov 19 |
| Q4 2025 · Jun 30derived | — | — | — | — | −$702K | — | 2.38 | −$1.5M | $20K | −$1.6M | Oct 8 |
| Q3 2025 · Mar 31 | — | — | — | — | −$1.4M | — | -1.35 | −$3.4M | $2K | −$3.4M | May 15 |
| Q2 2025 · Dec 31 | — | — | — | — | −$908K | — | -0.05 | −$842K | −$11K | −$831K | Feb 13 |
| Q1 2025 · Sep 30 | — | — | — | — | −$266K | — | -0.01 | −$30K | $20K | −$50K | Nov 19 |
| Q4 2024 · Jun 30derived | — | — | — | — | −$809K | — | -0.04 | −$476K | $53K | −$529K | Oct 8 |
| Q3 2024 · Mar 31 | — | — | — | — | −$1.1M | — | -0.05 | −$1.1M | −$27K | −$1M | May 15 |
| Q2 2024 · Dec 31 | — | — | — | — | −$145K | — | -0.01 | — | — | — | Apr 15 |
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Jun 30 | — | — | — | −$3.3M | — | -0.16 | −$5.8M | $32K | −$5.9M | — | — |
| FY2024 · to Jun 30 | — | — | — | −$2.8M | — | -0.14 | −$2.1M | $74K | −$2.2M | — | — |
Every number comes from Advanced Biomed Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.